Author ORCID Identifier
Dylan Thibaut: https://orcid.org/0000-0002-8739-9688
Connor Sweeney: https://orcid.org/0000-0002-1854-6891
Shannon South: https://orcid.org/0000-0002-0755-823X
Mohamed Hussein, PhD: https://orcid.org/0000-0003-0895-1129
Abstract
Background: Human leukocyte antigen (HLA) class II has shown potential in determining prognosis, understanding medication reactions, and predicting onset of Graves’ disease. The aim of this study is to further investigate the association between Graves’ disease and HLA class II, specifically HLA-DQ and HLA-DR, via meta-analysis to find HLAs that can be further examined for prognostic reasons.
Methods: Statistical analysis was performed to determine if variants of HLA-DQA1, HLA-DQB1, or HLA-DRB1 were associated with significantly altered odds of Graves’ disease. A minimum of three studies pertaining to a particular HLA was required for inclusion. Studies were excluded if they lacked inclusion criteria.
Results: 27 studies were included. Odds of associated HLAs in Graves’ disease patients versus controls were increased for HLA-DQA1*03:01 (OR = 1.30 [1.03, 1.63], I² =0%, p
Discussion: These findings offer new connections between HLAs and Graves’ disease that may be applied to prognosis, treatment, and autoimmune mechanistic understanding for MHC class II in Graves’ disease.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Recommended Citation
Thibaut D, Sweeney C, South S, Hussein M. Graves' Disease and Major Histocompatibility Complex Class II: A Meta-Analysis of HLA-DQ and HLA-DRB1. Advances in Clinical Medical Research and Healthcare Delivery. 2023; 3(1). doi: 10.53785/2769-2779.1136.
Publisher Note
All articles published in ACMRHD are distributed with a Creative Commons CC BY-NC 4.0 license. Under this license, authors hold the copyright to their work and have the right to share or adapt the article with no restrictions, as long as the author(s) and source are cited, and the use is for noncommercial purposes. This policy went into effect November 1, 2023, and applies retroactively to all articles published in ACMRHD prior to that date, as well.